P1132: LONG-TERM RESPONSES WITH LONCASTUXIMAB TESIRINE: UPDATED RESULTS FROM LOTIS-2, THE PIVOTAL PHASE 2 STUDY IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA

Antzeko izenburuak

• P1132: LONG-TERM RESPONSES WITH LONCASTUXIMAB TESIRINE: UPDATED RESULTS FROM LOTIS-2, THE PIVOTAL PHASE 2 STUDY IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
  nork: Paolo F Caimi, et al.
  Argitaratua: (2023-08-01)
• C075 | INITIAL RESULTS FROM LOTIS-7: A PHASE 1B STUDY OF LONCASTUXIMAB TESIRINE PLUS GLOFITAMAB IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
  nork: P.L. Zinzani, et al.
  Argitaratua: (2025-09-01)
• PB2118: PHASE 3 RANDOMIZED STUDY OF LONCASTUXIMAB TESIRINE IN COMBINATION WITH RITUXIMAB (LONCA-R) VERSUS IMMUNOCHEMOTHERAPY IN PATIENTS WITH R/R DLBCL (LOTIS-5)
  nork: M. Hamadani, et al.
  Argitaratua: (2022-06-01)
• P1717: HEALTH-RELATED QUALITY OF LIFE AND TOLERABILITY OF LONCASTUXIMAB TESIRINE IN HIGH-RISK PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA TREATED IN A PHASE 2 CLINICAL TRIAL (LOTIS 2)
  nork: A. Spira, et al.
  Argitaratua: (2022-06-01)
• Vesiculobullous eruption with loncastuximab tesirine in a patient with relapsed follicular lymphoma
  nork: Riyad N.H. Seervai, MD, PhD, et al.
  Argitaratua: (2024-11-01)